Literature DB >> 3505231

Phenyl-T-butyl-nitrone is active against traumatic shock in rats.

G P Novelli1, P Angiolini, R Tani, G Consales, L Bordi.   

Abstract

Oxygen free-radicals appear to be involved in the pathogenesis of shock; therefore trapping of these radicals would modify the evolution of experimental shock. Experiments were performed on rats submitted to 100% lethal whole body trauma (rotating drum) and their survival, pathology, acid-base status and hematocrit level observed. The spin trapping agent phenyl-t-butyl-nitrone (PBN) was administered before trauma (50, 100, 150 mg/kg i.p.) or at various intervals (30, 60 minutes) after establishment of a severe traumatic shock. It appeared that PBN administration was highly effective both in prevention and in reversion of traumatic shock in rats.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3505231     DOI: 10.3109/10715768609080971

Source DB:  PubMed          Journal:  Free Radic Res Commun        ISSN: 8755-0199


  14 in total

Review 1.  Nitrones as therapeutics.

Authors:  Robert A Floyd; Richard D Kopke; Chul-Hee Choi; Steven B Foster; Sabrina Doblas; Rheal A Towner
Journal:  Free Radic Biol Med       Date:  2008-08-29       Impact factor: 7.376

Review 2.  Nitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines.

Authors:  Robert A Floyd; Hugo C Castro Faria Neto; Guy A Zimmerman; Kenneth Hensley; Rheal A Towner
Journal:  Free Radic Biol Med       Date:  2013-02-16       Impact factor: 7.376

3.  Beneficial effects of Mn(III)tetrakis (4-benzoic acid) porphyrin (MnTBAP), a superoxide dismutase mimetic, in zymosan-induced shock.

Authors:  S Cuzzocrea; G Costantino; E Mazzon; A De Sarro; A P Caputi
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

Review 4.  Potential implication of the chemical properties and bioactivity of nitrone spin traps for therapeutics.

Authors:  Frederick A Villamena; Amlan Das; Kevin M Nash
Journal:  Future Med Chem       Date:  2012-06       Impact factor: 3.808

Review 5.  Nitrone-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke.

Authors:  Kirk R Maples; A Richard Green; Robert A Floyd
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 6.  Translational research involving oxidative stress and diseases of aging.

Authors:  Robert A Floyd; Rheal A Towner; Ting He; Kenneth Hensley; Kirk R Maples
Journal:  Free Radic Biol Med       Date:  2011-04-14       Impact factor: 7.376

7.  Alpha-phenyl-N-tert-butylnitrone (PBN) prevents light-induced degeneration of the retina by inhibiting RPE65 protein isomerohydrolase activity.

Authors:  Md Nawajes A Mandal; Gennadiy P Moiseyev; Michael H Elliott; Anne Kasus-Jacobi; Xiaoman Li; Hui Chen; Lixin Zheng; Olga Nikolaeva; Robert A Floyd; Jian-Xing Ma; Robert E Anderson
Journal:  J Biol Chem       Date:  2011-07-24       Impact factor: 5.157

8.  Preclinical Characterization of Antioxidant Quinolyl Nitrone QN23 as a New Candidate for the Treatment of Ischemic Stroke.

Authors:  Emma Martínez-Alonso; Alejandro Escobar-Peso; Alicia Aliena-Valero; Germán Torregrosa; Mourad Chioua; Rocío Fernández-Serra; Daniel González-Nieto; Youness Ouahid; Juan B Salom; Jaime Masjuan; José Marco-Contelles; Alberto Alcázar
Journal:  Antioxidants (Basel)       Date:  2022-06-16

9.  Synthesis, Neuroprotection, and Antioxidant Activity of 1,1'-Biphenylnitrones as α-Phenyl-N-tert-butylnitrone Analogues in In Vitro Ischemia Models.

Authors:  Beatriz Chamorro; David García-Vieira; Daniel Diez-Iriepa; Estíbaliz Garagarza; Mourad Chioua; Dimitra Hadjipavlou-Litina; Francisco López-Muñoz; José Marco-Contelles; María Jesús Oset-Gasque
Journal:  Molecules       Date:  2021-02-20       Impact factor: 4.411

10.  Melatonin and Nitrones As Potential Therapeutic Agents for Stroke.

Authors:  Alejandro Romero; Eva Ramos; Paloma Patiño; Maria J Oset-Gasque; Francisco López-Muñoz; José Marco-Contelles; María I Ayuso; Alberto Alcázar
Journal:  Front Aging Neurosci       Date:  2016-11-23       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.